ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results

Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to immunotherapy. BR.36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of molecular response-adaptive immuno-chemotherapy for patients with lung cancer. In the first of two independent stages, 50 patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Anagnostou, Valsamo, Ho, Cheryl, Nicholas, Garth, Juergens, Rosalyn Anne, Sacher, Adrian, Fung, Andrea S., Wheatley-Price, Paul, Laurie, Scott A., Levy, Benjamin, Brahmer, Julie R., Balan, Archana, Niknafs, Noushin, Avrutin, Egor, Zhu, Liting, Sausen, Mark, Bradbury, Penelope A., O’Donnell-Tormey, Jill, Gaudreau, Pierre Olivier, Ding, Keyue, Dancey, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579094/
https://www.ncbi.nlm.nih.gov/pubmed/37814061
http://dx.doi.org/10.1038/s41591-023-02598-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579094/
https://www.ncbi.nlm.nih.gov/pubmed/37814061
http://dx.doi.org/10.1038/s41591-023-02598-9

Ejemplares similares